Lemborexant for Insomnia in a Patient With Dementia: An N-of-1 Trial
Launched by NOVA SCOTIA HEALTH AUTHORITY · Oct 16, 2023
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new medication called lemborexant to see how well it helps people with early-onset dementia who also struggle with insomnia, which is trouble sleeping. Insomnia can be particularly hard for both patients and their caregivers, and traditional sleeping pills often come with serious side effects, especially for older adults. Lemborexant works differently from these traditional medications and may not cause the same problems, such as excessive drowsiness or worsening sleep issues once stopped.
To participate in this trial, individuals need to be diagnosed with early-onset dementia and have significant insomnia. The trial is currently recruiting participants of all genders. Those who take part will have the opportunity to see how well they tolerate lemborexant and whether it helps improve their sleep. This study aims to provide valuable information about the effectiveness of this medication for people with early-onset dementia, potentially leading to better treatment options in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Identified by clinician investigator to have early-onset dementia and a significant component of insomnia.
- Exclusion Criteria:
- • Known sleep disorders that are contraindications for orexin antagonist therapy.
About Nova Scotia Health Authority
The Nova Scotia Health Authority (NSHA) is a leading healthcare organization dedicated to enhancing the health and well-being of individuals and communities across Nova Scotia, Canada. As the largest provider of health services in the province, NSHA is committed to advancing clinical research and innovation through rigorous clinical trials that aim to improve patient care and outcomes. With a focus on collaboration, NSHA engages healthcare professionals, researchers, and patients to address pressing health challenges and contribute to the global body of medical knowledge. By fostering a culture of evidence-based practice and continual improvement, NSHA plays a pivotal role in shaping the future of healthcare delivery in the region.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Halifax, Nova Scotia, Canada
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported